Immunotherapies called checkpoint inhibitors have helped change the way a number of cancers are treated by blocking a tumor cell’s ability to hide from the immune system.
Some patients don’t respond, however, or develop resistance to these drugs. Iteos Therapeutics has raised $125 million to advance new cancer treatments it is developing to target two mechanisms it believes aid in the suppression of an anti-tumor immune response in the area immediately surrounding a tumor, or the tumor microenvironment.
The company’s lead program, EOS-850, is designed to target a receptor in the adenosine pathway. The investigational drug is in early-stage testing by… Read more »
UNDERWRITERS AND PARTNERS
